Annual Report

Overview

The report presents Mesoblast's first dedicated ESG Statement, identifying eight material topics spanning governance, ethics, human capital, patient safety, supply chain, healthcare access, and environmental impacts. The company states that its Board oversees ESG-related risks and opportunities, supported by the Nomination and Remuneration Committee and Audit and Risk Committee. Its access-to-healthcare initiatives included providing remestemcel-L at no cost to more than 250 children under compassionate use arrangements. The report also records 77 employees at June 30, 2022 and FY2022 revenue of 10,214 in U.S. dollars, in thousands.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: Ends 30 June 2022
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services